BREAKING WEGOVY: FDA Issues Harshest Inspection Outcome to Novo Over US Plant

What does this mean for patients using Ozempic and Wegovy

Original posted at obesity.news/ on Oct 14, 2025

This week’s episode of On The Pen: The Weekly Dose is one you don’t want to miss.

The FDA just hit Novo Nordisk’s Wegovy plant with its harshest classification — the kind that makes you question what “FDA approved” really means. At the same time, researchers discovered that GLP-1s can light up PET scans in ways that mimic cancer, sparking a wave of confusion across imaging labs.

This article is reader-supported on Substack.

To receive new posts and support my work,

consider becoming a free or paid subscriber.

Subscribe

We also dive into new data showing that while GLP-1 medications have changed the game, metabolic surgery still sets the gold standard for severe obesity — and how new minimally invasive options like Fractyl’s Revita procedure could one day bridge that gap.

And if that wasn’t enough, Europe’s top obesity researchers just made it official: semaglutide and tirzepatide are now first-line drug treatments for obesity.

Four massive stories. One conversation that connects them all.

🎧 Watch or listen to this week’s episode of On The Pen: The Weekly Dose

Because the ground under obesity medicine is shifting fast, and you deserve to understand what’s happening before the mainstream headlines twist it!

VISIT OUR PODCAST SPONSORS TO SUPPORT OUR WORK:

This article is reader-supported on Substack.

To receive new posts and support my work,

consider becoming a free or paid subscriber.

Subscribe